These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36853604)

  • 1. Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk.
    Brown CJ; Chang LS; Hosomura N; Malmasi S; Morrison F; Shubina M; Lan Z; Turchin A
    JAMA Netw Open; 2023 Feb; 6(2):e231047. PubMed ID: 36853604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
    Willeit P; Ridker PM; Nestel PJ; Simes J; Tonkin AM; Pedersen TR; Schwartz GG; Olsson AG; Colhoun HM; Kronenberg F; Drechsler C; Wanner C; Mora S; Lesogor A; Tsimikas S
    Lancet; 2018 Oct; 392(10155):1311-1320. PubMed ID: 30293769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
    Thanassoulis G; Sniderman AD; Pencina MJ
    JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study.
    Kim JY; Choi J; Kim SG; Kim NH
    Cardiovasc Diabetol; 2022 Feb; 21(1):28. PubMed ID: 35193571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men.
    Moreno-Arellano S; Delgado-de-Mendoza J; Santi-Cano MJ
    Nutr Metab Cardiovasc Dis; 2018 Aug; 28(8):810-815. PubMed ID: 29754716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
    Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
    J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Strict Versus Lenient Cholesterol Lowering with Cardiac Outcomes, Diabetes Progression and Complications, and Mortality in Patients with Diabetes Treated with Statins: Is Less More?
    Odeleye V; Masarweh O; Restrepo J; Alvarez CA; Mansi IA
    Drug Saf; 2023 Nov; 46(11):1105-1116. PubMed ID: 37782373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol.
    Tsujimoto T; Kajio H; Sugiyama T
    Am J Cardiol; 2017 Dec; 120(11):1947-1954. PubMed ID: 28951019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus.
    Burkholder GA; Muntner P; Zhao H; Mugavero MJ; Overton ET; Kilgore M; Drozd DR; Crane HM; Moore RD; Mathews WC; Geng E; Boswell S; Floris-Moore M; Rosenson RS
    J Clin Lipidol; 2018; 12(4):988-998.e5. PubMed ID: 29853312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
    Boekholdt SM; Hovingh GK; Mora S; Arsenault BJ; Amarenco P; Pedersen TR; LaRosa JC; Waters DD; DeMicco DA; Simes RJ; Keech AC; Colquhoun D; Hitman GA; Betteridge DJ; Clearfield MB; Downs JR; Colhoun HM; Gotto AM; Ridker PM; Grundy SM; Kastelein JJ
    J Am Coll Cardiol; 2014 Aug; 64(5):485-94. PubMed ID: 25082583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
    Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
    JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.